{"id":"hs-10296","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperphosphatemia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Stomatitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HS-10296 targets FGFR kinase activity to inhibit downstream proliferation and survival pathways in tumors with FGFR alterations. By selectively blocking FGFR signaling, the drug aims to suppress tumor growth in cancers driven by FGFR mutations, fusions, or amplifications.","oneSentence":"HS-10296 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:47:59.029Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"FGFR-altered solid tumors"},{"name":"Urothelial carcinoma with FGFR alterations"}]},"trialDetails":[{"nctId":"NCT07130916","phase":"PHASE1","title":"A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2024-12-05","conditions":"Non-Small Cell Lung Cancer","enrollment":20},{"nctId":"NCT06417008","phase":"PHASE2, PHASE3","title":"A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Hansoh BioMedical R&D Company","startDate":"2024-05-28","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":1080},{"nctId":"NCT06926413","phase":"PHASE1","title":"A Study Evaluating the Effect of Aumolertinib on the Pharmacokinetics of Midazolam in Patients With NSCLC","status":"RECRUITING","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2025-02-20","conditions":"Non Small Cell Lung Cancer","enrollment":20},{"nctId":"NCT04423185","phase":"PHASE2","title":"PLATFORM Study of Precision Medicine for Rare Tumors","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2020-08-15","conditions":"Rare Tumor","enrollment":770},{"nctId":"NCT06227897","phase":"PHASE2","title":"Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA).","status":"WITHDRAWN","sponsor":"Sun Yat-sen University","startDate":"2024-06-01","conditions":"Lung Cancer","enrollment":""},{"nctId":"NCT04923906","phase":"PHASE3","title":"Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2021-08-11","conditions":"Non-small Cell Lung Cancer","enrollment":624},{"nctId":"NCT04687241","phase":"PHASE3","title":"Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2021-04-30","conditions":"Non-small Cell Lung Cancer","enrollment":192},{"nctId":"NCT04685070","phase":"PHASE2","title":"Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2021-12-14","conditions":"Non-small Cell Lung Cancer Stage III","enrollment":56},{"nctId":"NCT05493501","phase":"PHASE3","title":"Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"EQRx International, Inc.","startDate":"2022-12-14","conditions":"NSCLC","enrollment":8},{"nctId":"NCT04808752","phase":"PHASE2","title":"Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2021-07-09","conditions":"Lung Cancer","enrollment":63},{"nctId":"NCT04922138","phase":"PHASE2","title":"Aumolertinib Adjuvant Therapy of Resectable Stage I EGFRm+ NSCLC With High-grade Patterns","status":"UNKNOWN","sponsor":"Baohui Han","startDate":"2022-01-14","conditions":"Lung Cancer","enrollment":104},{"nctId":"NCT05199610","phase":"PHASE1","title":"An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of EQ143","status":"COMPLETED","sponsor":"EQRx International, Inc.","startDate":"2022-03-30","conditions":"Severe Hepatic Impairment","enrollment":12},{"nctId":"NCT02981108","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC","status":"UNKNOWN","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2017-05-08","conditions":"Nonsmall Cell Lung Cancer","enrollment":364},{"nctId":"NCT03849768","phase":"PHASE3","title":"A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients","status":"UNKNOWN","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2019-02-01","conditions":"Non Small Cell Lung Cancer","enrollment":429},{"nctId":"NCT05662813","phase":"PHASE2","title":"Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy","status":"UNKNOWN","sponsor":"West China Hospital","startDate":"2022-11-09","conditions":"Non-small Cell Lung Cancer","enrollment":55},{"nctId":"NCT03904823","phase":"PHASE2","title":"A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLC","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-04-25","conditions":"EGFR-mutant Non-Small Cell Lung Cancer","enrollment":58},{"nctId":"NCT04951635","phase":"PHASE3","title":"A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2021-03-18","conditions":"Non-small Cell Lung Cancer","enrollment":150},{"nctId":"NCT04951648","phase":"PHASE3","title":"A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation","status":"UNKNOWN","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2021-07-15","conditions":"Non-small Cell Lung Cancer","enrollment":220},{"nctId":"NCT04882345","phase":"PHASE2","title":"Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment","status":"UNKNOWN","sponsor":"Shanghai Chest Hospital","startDate":"2021-07-15","conditions":"Lung Cancer, EGFR Gene Mutation","enrollment":40},{"nctId":"NCT04870190","phase":"PHASE3","title":"Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases","status":"UNKNOWN","sponsor":"Shanghai Chest Hospital","startDate":"2021-06-01","conditions":"NSCLC","enrollment":232},{"nctId":"NCT04643847","phase":"PHASE2","title":"A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain Metastases","status":"UNKNOWN","sponsor":"First People's Hospital of Hangzhou","startDate":"2020-11-30","conditions":"EGFR Positive Non-small Cell Lung Cancer, Brain Metastases","enrollment":47},{"nctId":"NCT04455594","phase":"PHASE2","title":"Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2020-10","conditions":"Non-Small Cell Lung Cancer Stage IIIA","enrollment":168}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Investigational Product"],"phase":"phase_3","status":"active","brandName":"HS-10296","genericName":"HS-10296","companyName":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","companyId":"jiangsu-hansoh-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HS-10296 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells. Used for FGFR-altered solid tumors, Urothelial carcinoma with FGFR alterations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}